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Diclofenac sodium is a nonsteroidal anti-
inflammatory drug (NSAID) that it used for the
treatment of rheumatic diseases, minor and medium
pain, and post surgery analgesia in medicine.
Patients who are given formulations of diclofenac or
other NSAIDs as a therapeutic strategy often suffer
from the gastrointestinal tract complications (1-3).
In order to decrease the adverse effects or to
increase the therapeutic analgesic effect, diclofenac
was orally administered in composed tablets com-
prising also misoprostol (4) and topically in a for-
mulation comprising e.g., a spasmolytic agent -
papaverine hydrochloride (5). In the literature can
be found reports of a separate administration of
diclofenac and papaverine for the relief of pain in
patients with renal colic (6, 7). There are no reports
of a formulation comprising diclofenac sodium and
papaverine hydrochloride in a composed dosage
form, therefore, we decided to prepare tablets con-
sisting of DIC and PAP for oral administration for
analgesic effect. Next, the tablets comprising the
two drugs were patented (8).
In the literature, there are no reports regard-
ing the relationship of pharmacokinetic parame-
ters between DIC and PAP. Diclofenac is almost
completely absorbed after oral administration, it
is subjected to first-pass metabolism so that about
50% of the drug reaches the systemic circulation
in the unchanged form. More than 99% is bound
to plasma proteins, primarily to albumin (3, 9,
10). Diclofenac exhibits a terminal half-life of 1-
2 h (3, 9). Metabolism of diclofenac is mediated
by both glucuronidation and oxidative biotrans-
formation (11). The oxidative metabolism of
diclofenac is catalyzed by two enzymes of the
cytochrome P450 family, namely CYP2C9 and
CYP3A4 (12). Diclofenac is metabolized to 4í-
hydroxydiclofenac and 5-hydroxydiclofenac, 3í-
hydroxydiclofenac and 4í,5-dihydroxydiclofenac
(13, 14). They are then excreted in the form of
glucuronide and sulfate conjugates, mainly in the
urine (about 60%) but also in the bile (about 35%)
and less than 1% is excreted as unchanged
diclofenac (3).
Papaverine is completely absorbed by the gas-
trointestinal tract and metabolized principally by the
liver. Papaverine in about 90% bound to plasma pro-
teins. The biological half-life is reported to be
between 1 and 2 h (3). The major route of biotrans-
formation is O-demethylation to the corresponding
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phenolic metabolites (15). Several phenolic metabo-
lites have been identified: 4í-desmethylpapaverine
(which predominantes in most cell systems), 6-
desmethylpapaverine, 7í-desmethylpapaverine,
4í,6-didesmethylpapaverine and 3í-desmethylpa-
paverine (16-18). Papaverine is excreted in the
urine, almost entirely as glucuronide-conjugated
phenolic metabolites (3).
To test the pharmacokinetics and bioavailabil-
ity of DIC and PAP given in a single formulation,
it was necessary to develop a method for determi-
nation of DIC and PAP in rabbit plasma.
According to the literature, several HPLC methods
using different clean-up procedures, including
direct injection, protein precipitation (19-21),
solid-phase extraction (SPE) (22), liquid-liquid
extraction (LLE) (23-26) and column switching
(27) with UV (24-29), fluorimetric (20) or electro-
chemical detection (30) HPTLC (31) and HPLC-
MS/MS (32), GC-MS (33, 34) were applied to
determine diclofenac in animal or human plasma.
Papaverine hydrochloride in biological fluids was
assayed using HPLC (35-37), GLC (38), and GC
(39) methods. 
There are no data about pharmacokinetics of
diclofenac sodium and papaverine hydrochloride
after administration in composed formulation and
there is no HPLC method for simultaneous determi-
nation of diclofenac sodium and papaverine
hydrochloride levels in plasma. Therefore, the aim
of this study was to examine the pharmacokinetics
of DIC and PAP after oral administration of com-
posed tablets to rabbits and develop and validate the
HPLC method.
EXPERIMENTAL
Reagents and chemicals
Diclofenac sodium (DIC) was produced by
Caesar and Loretz, GmbH, Hilden, Germany,
papaverine hydrochloride (PAP) was purchased
from Galfarm PPH, Cefarm Lublin, Poland, and
phenacetin (IS) from POCh Gliwice, Poland.
Polyvinylpyrrolidone K 22 (PVP), mannitol (M) and
potato starch (PS) were the products of Merck,
Germany. Chloroform was obtained from POCh
Gliwice, Poland. Methanol and water (HPLC grade)
were purchased from Merck, Germany and other
reagents were of analytical grade. 
Preparation of tablets
Composition and preparation of tablets (T)
containing DIC and PAP were described in the
patent (8). Tablets containing only one substance,
DIC (T-DIC) or PAP only (T-PAP), were obtained
in the same manner as described in this patent, but
composition contained only one active substance.
One dose of tablets (T) consists of 50 mg DIC,
20 mg PAP and excipients such as 70 mg PVP, 70
mg M and 90 mg PS to obtain 300 mg of weight.
One dose of tablets (T-DIC) consists of 50 mg DIC
and excipients to obtain 280 mg of weight. One dose
of tablets (T-PAP) consists of 20 mg PAP and excip-
ients to obtain 250 mg of weight. 
Tablets were obtained by direct compression of
granules, which were previously prepared by wet
granulation method. Granules were obtained by
mixing and wetting of the powders with PVP solu-
tion until a mass of suitable consistency was
obtained. Then, the wet mass was granulated using a
Table 1. Physical properties of prepared tablets.
Test 
Results   
T T-DIC T-PAP  
Weight (mg)
mean SD 
300.54 ± 2.45 281.32 ± 1.55 249.68 ± 1.87
Thickness
(mm) SD 
4.02 ± 0.02 3.85 ± 0.01 3.8 ± 0.02
Disintegration
time (min) SD 
7 ± 2.5 6 ± 1.5 5 ± 2.1
Hardness (kG/mm2),
SD 
0.105 ± 0.01 0.1 ± 0.01 0.105 ± 0.03
Friability (%) 0.09 0.22 0.16  
Drug content
(%) DIC, SD 99.08 ± 1.17 100.04 ± 3.93 
(%) PAP, SD 100.05 ± 1.76 97.35 ± 1.23 
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rotary granulator (Erweka, Germany) and a 1.6 mm
mesh screen. Granules were dried in a hot air oven
(Memmert INB-500) at 40OC for 1 h. The dried
granules (moisture 3-5%) were sieved through a 1.6
mm mesh screen. The tablets were obtained from
these granules in a press tableting machine (Erweka,
Germany) with 9 mm concave punches. 
Physical properties of tablets
The tablets were tested as per standard proce-
dure for weight variation (n = 20), thickness (n =
20), hardness (n = 6), friability (n = 20), disintegra-
tion time (n = 6) and drug content (n = 10) (Table 1).
Weight uniformity test
For each formulation, twenty tablets were
selected randomly and weighed together and their
mean weight was calculated. Next, they were indi-
vidually weighed using a weighing balance (Ohaus
AV 513C, USA).
Tablet dimensions
Tablet diameter and thickness were measured
using a Vernier Caliper (Digital Caliper 0-150 mm,
Comparator).
Hardness test
Hardness of tablet was determined by using an
Erweka tablet hardness tester (Erweka, Germany). 
Friability test
An Erweka friabilator (Erweka, Germany) was
used for the test. Twenty tablets were weighed, sub-
jected to attrition at 25 rpm for 4 min and reweighed
afterwards. The percentage loss in weight equivalent
to friability was calculated from the equation below:
Friability (%) = (loss in weight/initial weight) ◊ 100.
Disintegration time
Disintegration time was measured by using an
Erweka apparatus (Germany). Each of six tablets
was put into a basket-rack in a vessel and was cov-
ered with a disk. After the apparatus had been turned
on, the disintegration time of the tablets was
observed.
Drug content analysis 
Ten tablets from each series were selected at
random, weighed together and the mean weight was
determined. The tablets were crushed together and
weighed exactly 300 mg (T), 280 mg (T-DIC) or
250 mg (T-PAP), when in powder form (n = 6), dis-
solved in methanol in a 50 mL volumetric flask, fil-
tered using the Whatman filter and appropriately
diluted with methanol. Drug content of DIC and
PAP were analyzed by HPLC method published in
earlier report (40). 
Chromatographic conditions
The chromatographic separation of DIC, PAP
and the IS (phenacetin) was achieved with a Perkin
Elmer 200 HPLC system consisting of the 200 series
pump, the 200 series autosampler equipped with a
200 µL loop, the 200 series UV/VIS detector, the
200 series vaccum degasser and a Zorbax SB C18 
5-µm column (150 ◊ 4.6 mm, Agilent, USA). 
The mobile phase consisted of methanol and
water (55 : 45, v/v), and the flow rate was 0.8
mL/min. The injection volume was 100 µL. The UV
detection wavelengths at maximum absorbance of
DIC and PAP at 280 nm and 238 nm, respectively,
were chosen. The samples were injected twice
because the Perkin Elmer 200 HPLC system enabled
a detection for only one wavelength.
Calibration standards
Stock solutions of DIC (250 µg/mL) and PAP
(100 µg/mL) were prepared in mobile phase solution
(methanol-water, 55 : 45, v/v) and stored at 4OC
wrapped in aluminum foil. The working solutions at
concentrations of 0.5, 1.25, 2.5, 5, 12.5, 25 and 50
µg/mL of DIC and 0.5, 1, 2, 5, 10, 20, 40 and 60
µg/mL of PAP were prepared by serial dilution of
DIC or PAP stock solutions in mobile phase. The IS
working solution (20 µg/mL) was also prepared by
dilution of the IS stock solution (100 µg/mL) with
mobile phase. 
The calibration standards were obtained by
appropriate dilution of working solutions with
mobile phase. The calibration standards were pre-
pared on the same day at concentrations of 0.05,
0.125, 0.25, 0.5, 1.25, 2.5 and 5 µg/mL of DIC and
0.05, 0.1, 0.2, 0.5, 1, 2, 4 and 6 µg/mL of PAP, by
spiking 1 mL blank rabbit plasma with 100 µL of
DIC or PAP working solutions and 100 µL of IS
working solution. 
Sample and calibration standard preparation
Briefly, a 1 mL of blank rabbit plasma, spiked
plasma (calibration standard sample) or pharmaco-
kinetic study plasma sample was initially spiked
with 100 µL of IS working solution and then 1.5 mL
of 1 M hydrochloric acid was added. The mixture
was shaken for the period of 10 min. To the obtained
mixture, 3 mL of chloroform was added, shaken for
10 min and centrifuged at 3600 rpm for 10 min. The
supernatant was separated and evaporated to dryness
under nitrogen gas. The residue was reconstituted
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with 400 µL of mobile phase and 100 µL aliquot of
resulting solution was injected into HPLC appara-
tus. The samples setting into the vials were immedi-
ately assayed. Having obtained a chromatogram at a
wavelength of 280 nm, 100 µL of the aliquot was
injected once again and assayed at a wavelength of
238 nm for the assay of DIC and PAP, respectively. 
Selectivity 
The selectivity of the method was tested by
comparing the chromatograms of blank plasma con-
trols from six rabbits with that of plasma spiked with
DIC, PAP and IS. 
Sensitivity
The calibration standard at the lowest concen-
tration, yielding a precision with relative standard
deviations (RSD) less than 20% and accuracy with-
in 20% of the nominal concentration, was consid-
ered to be the lower limit of quantification.
Calibration curve
Calibration standards at concentrations of 0.05,
0.125, 0.25, 0.5, 1.25, 2.5 and 5 µg/mL of DIC and
0.05, 0.1, 0.2, 0.5, 1, 2, 4 and 6 µg/mL of PAP (n =
2) were freshly prepared as described above and
assayed on the same day. This assay was repeated
for five consecutive days with freshly prepared cali-
bration standards. The subsequent five calibration
curves (y = ax + b), represented by the plots of the
peak area of DIC to IS or PAP to IS (y) versus the
concentration of the calibration standards (x), were
generated and obtained by linear least-squares
regression as the mathematical model.
Accuracy and precision
In order to validate the intra-day accuracy and
precision, the samples of DIC (0.05, 0,25, 1.25 and
5 µg/mL) and PAP (0.05, 0.2, 2, 6 µg/mL) were
freshly prepared and analyzed on the same day (n =
5). To validate the inter-day accuracy and precision,
the intra-day accuracy and precision assay was
repeated for three consecutive days. Data are pre-
sented in Table 2.
Accuracy was calculated by comparing the
average concentration found to the known concen-
tration, and was expressed in percentage as relative
error. Precision was evaluated by calculating the
RSD of measured concentrations at each level.
Recovery
The extraction recoveries of DIC and PAP
from rabbit plasma at levels (0.05, 0.25, 1.25 and 5
µg/mL of DIC and 0.05, 0.2, 1, 4 µg/mL of PAP)
were determined by comparing mean peak area of
DIC/IS or PAP/IS samples to that of unextracted
DIC or PAP standards in mobile phase at equivalent
DIC or PAP level spiked with IS and expressed in
percentage, respectively.
Stability of samples
Short-term stability of plasma samples was
examined by supplementing blank plasma with
appropriate amounts of working solutions of DIC
and PAP to obtain 0.05, 0.25, 1.25, 5.0 µg/mL of
DIC and 0.05, 0.2, 2.0, 6.0 µg/mL of PAP. Each
sample was analyzed at room temperature for 48 h
(every 4 h), including their residence time in an
autosampler. 
Table 2. Intra- and inter-day validation of the method (precision and accuracy) (n = 5). 
Intra-day Inter-day  
Added Found
Precision
Accuracy Found
Precision 
Accuracy
concentration concentration
(% RSD)
(relative concentration
(% RSD)
(relative
(µg/mL)   (µg/mL)   error, %)   (µg/mL)    error, %)
DIC  
0.05 0.0477 7.6 4.6 0.0464 5.9 7.2  
0.25 0.2395 3.3 4.2 0.2368 4.0 5.3  
1.25 1.1588 4.4 7.3 1.1738 2.1 6.1  
5 4.6752 4.5 6.5 4.8122 1.7 3.8  
PAP  
0.05 0.0474 8.7 5.2 0.0482 7.6 3.6  
0.2 0.1954 3.4 2.3 0.1952 4.5 2.4  
2 1.8463 2.3 7.7 1.8823 5.2 5.9  
6 5.4871 7.0 8.5 5.6401 4.8 6.0 
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The long-term freezer stability of DIC and PAP
in rabbit plasma was assessed by analysis after 30
days of storage at -20OC. The concentration of the
stability of the samples (0.05, 0.25, 1.25, 5.0 µg/mL
for DIC and 0.05, 0.2, 2.0, 6.0 µg/mL for PAP) was
compared to the mean of back-calculated values for
the standards at the appropriate concentration from
the first day of the long term stability testing. 
The long-term freeze-thaw stability of the
active substances at concentrations 0.05, 0.25, 1.25,
5.0 µg/mL for DIC and 0.05, 0.2, 2.0, 6.0 µg/mL for
PAP in plasma was analyzed in triplicate after 1, 2
and 30 days of storage at -20OC.
Pharmacokinetic study
Animals
The experiments were carried out on randomly
selected male Berg rabbits weighing 2.5-3.0 kg, pur-
chased from the licensed breeder (Lisowski,
Parczew, Poland). The animals were kept in cages
(one per cage) on a 12-hour day/night cycle with
free access to food and water. Each experimental
group consisted of 9-12 animals. The experimental
protocol was approved by the Local Ethics
Committee at the Medical University of Lublin
(license number 36/2007). All procedures were per-
formed in compliance with the requirements of
European convention for the protection of vertebrate
animals used for experimental and other scientific
purposes (ETS123, 1991).
Administration and sampling
Before the experiment, the rabbits were fasted
for the period of 12 h but water was available. 
On the first day of the test, the rabbits were divid-
ed into four groups and each group consisted of three
animals. DIC and PAP used for intravenous adminis-
tration were separately dissolved in sterile apyrogenic
saline. The first group of animals was given a single
intravenous injection of sterile apyrogenic physiologi-
cal saline (as negative control), the second group was
administered DIC at a dose of 12.5 mg/kg body weight
(b.w.), the third group was injected with PAP at a dose
of 5 mg/kg b.w. and the fourth group with DIC (12.5
mg/kg b.w.) and PAP (5 mg/kg b.w.). Intravenous
administration was performed in the marginal ear vein
of the rabbits at a volume of 0.5 mL/kg b.w. with ster-
ile disposable syringes and needles.
The next day, other rabbits were divided into
three groups and each group consisted of three ani-
mals. The first group was orally administered a
tablet with DIC (12.5 mg/kg b.w.), the second group
was given a tablet with PAP (5 mg/kg b.w.) and the
third group a tablet composed of DIC (12.5 mg/kg
b.w.) and PAP (5 mg/kg b.w.). The tablets were
administered via an orogastric tube with 100 mL of
water. Blood samples were withdrawn from the ear
vein at different time intervals: 0, 0.5, 1, 2, 3, and 4
h. These intervals were chosen because the biologi-
cal half-time of DIC and PAP is 1-2 h (3). In
humans, dogs and pigs the terminal elimination half-
lives (t1/2‚) of diclofenac have been reported to range
from 1.1 to 2.4 h (9, 41, 42). The blood was collect-
ed into heparinized tubes. Plasma was separated and
stored at -20OC till the analysis was carried out. All
of the plasma samples were analyzed within a week
after the separation.
After a lag period of 10 days, the animals were
crossed over and the experiments were repeated.
Finally, DIC and PAP were administered intra-
venously and orally in single and composed prepa-
rations six times (n = 6). The experiment was carried
out at room temperature. All preparations were
administered in the morning.
Calculations and statistics
The non-compartmental pharmacokinetic
analysis of DIC and PAP concentrations in plasma
versus time data were calculated using WinNonlin
1.1 software. The plasma concentration ñ time pro-
files following a single i.v. or p.o. doses were not
adequately fitted with a compartmental model.
Statistical analysis was carried out using SAS
9.1.3 (SAS Institute, Cary, NC, USA). The data
obtained were subjected to statistical analysis using
one-way ANOVA and Studentís t-test and a p value
of < 0.05 was considered as statistically significant.
RESULTS AND DISCUSSION
HPLC method development
Different mobile phases were used to deter-
mine either DIC or PAP in biological fluids by
HPLC (23-28, 34-36). There is no mobile phase for
simultaneous determination of DIC and PAP in bio-
logical matrices. In our previous study (40) on
simultaneous determination of DIC and PAP in
composed tablets, the HPLC method with a mobile
phase (methanol-water, 60 : 40, v/v) was developed.
Bearing those studies in mind, we tried to achieve a
proportion of solvents with an optimized separation
of the active substances. It was not easy because the
solubility of DIC and PAP is different (3). Various
proportions of methanol-water solvents in mobile
phase for determination of DIC in human plasma by
HPLC method can be found in the literature (30,
43). In our study, methanol-water (55 : 45, v/v) was
selected as the mobile phase for determination of
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Figure 1. Representative chromatograms of: (A1) DIC (4 µg/mL), PAP (2 µg/mL) and phenacetin (IS) (6 µg/mL) standards at 280 nm and
(A2) at 238 nm; (B1) blank rabbit plasma at 280 nm; (B2) blank rabbit plasma at 238 nm; (C1) rabbit plasma sample at 0.5 h after oral
administration of composed tablet comprising DIC and PAP and spiked with IS at 280 nm and (C2) at 238 nm; (D1) DIC for LLOQ; (D2)
PAP for LLOQ
A1 B1
A2 B2
C1 D1
C2 D2
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DIC and PAP in rabbit plasma because of its very
simple composition, and clear baseline separation of
DIC, PAP and IS was obtained (Fig. 1).
A number of NSAIDs have been used as an
internal standard for the analysis of DIC from the
biological matrices (19, 21, 31). Several substances
were tested as IS. There were very poor baseline
separations of ibuprofen, naproxen, ketoprofen or
indomethacin from DIC under the experimental con-
ditions used in the present study. However, using
phenacetin, clear line separation was achieved.
Phenacetin seemed to be the most appropriate drug
Table 3A. Stability of DIC in rabbit plasma samples.
Short-term stability (48 h) in an autosampler  
Concentration of 
DIC (µg/mL) 0.05 0.25 1.25 5.0  
Mean 0.055 0.2402 1.37 5.31 
SD 0.0013 0.0029 0.0351 0.0922 
CV (%) 2.36 1.21 2.56 1.74   
Long-term freezer stability (30 days)  
Concentration of 
DIC (µg/mL) 0.05 0.25 1.25 5
Mean 0.048 0.2576 1.29 5.15  
SD 0.0019 0.0057 0.0521 0.2138  
CV (%) 3.96 2.21 4.04 4.15   
Long-term freeze-thaw stability after three cycles (-20OC, 30 days)  
Concentration of 
DIC (µg/mL) 0.05 0.25 1.25 5 
% of the initial conc. 
of DIC after 30 days
97.43 98.32 97.12 98.89
SD 2.14 1.68 1.89 2.21  
CV (%) 0.02 0.02 0.02 0.02
Table 3B. Stability of PAP in rabbit plasma samples.
Short-term stability (48 h) in an autosampler  
Concentration of 
PAP (µg/mL) 0.05 0.2 2.0 6.0  
Mean 0.053 0.2073 2.09 6.25 
SD 0.001 0.0034 0.0321 0.0822 
CV (%) 1.89 1.64 1.54 1.32   
Long-term freezer stability (30 days)  
Concentration of 
PAP (µg/mL) 0.05 0.2 2.0 6.0
Mean 0.0512 0.2155 2.11 6.17  
SD 0.0023 0.0098 0.0821 0.2492  
CV (%) 4.49 4.55 3.89 4.04   
Long-term freeze-thaw stability after three cycles (-20OC, 30 days)  
Concentration of 
PAP (µg/mL) 0.05 0.2 2.0 6.0
% of the initial conc. 
of PAP after 30 days
98.32 99.03 95.78 98.16
SD 2.5 1.98 2.08  2.41  
CV (%) 0.03 0.02 0.02 0.02
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in the present assay and was chosen because it is
stable and does not endogenously exist in plasma.
Moreover, it did not interfere with the rabbit plasma
sample and it was well separated from DIC and
PAP.
Liquid-liquid extraction method was used for
sample preparation. When it comes to extracting
DIC from plasma after the acidification of the sam-
ple, hexane-isopropanol at different ratios (44, 45),
acetonitrile (19, 46), and dichloromethane (30) were
described in the literature. In our study, chloroform
was used as solvent for extraction after acidification
of plasma sample, because DIC and PAP are soluble
in acidic medium and IS in chloroform. This solvent
was adopted due to its high extraction efficiency and
little interference.
HPLC method validation
Selectivity
No interference of endogenous and extraneous
peaks with DIC, PAP and IS at their respective
retention times at two wavelengths (RTDIC = 2.87
min, RTIS = 4.77 min and RTPAP = 13.15 min at 280
nm and RTPAP = 13.14 min,  RTIS = 4.76 min, RTDIC
= 2.85 min at 238 nm) in blank rabbit plasma was
observed, as shown in Figure 1.
Sensitivity
The LLOQ of DIC and PAP in 1 mL rabbit
plasma was observed to be 0.05 µg/mL.
The limit of detection (LOD) for DIC amount-
ed to 0.015 µg/mL and for PAP to 0.02 µg/mL,
based on a signal to noise ratio > 3.
Linearity of calibration curve
The method has a good linearity over the range
of 0.05-5 µg/mL for DIC and 0.05-6 µg/mL for PAP.
The mean regression equation from five replicate
calibration curves was y = 0.1927 (± 0.0415) x +
0.0011 (± 0.00062) for DIC and y = 0.1449 (±
0.0267) x + 0.0033 (± 0.0017) for PAP. The square
root of mean correlation coefficient (r2) was 0.9974
for DIC and 0.9986 for PAP.
Precision and accuracy
The intra- and inter-day precision and accuracy
validation with samples of DIC and PAP are pre-
sented in Table 2. In the range of 0.05-5 µg/mL DIC,
the intra- and inter-day assay precision (RSD) varied
from 3.3 % to 7.6% and from 1.7% to 5.9%, respec-
tively. The intra- and inter-day accuracy (relative
error) ranged from 4.2% to 6.5% and from 3.8% to
7.2%, respectively. 
In the range of 0.05-6 µg/mL PAP, the intra-
and inter-day assay precision (RSD) varied from
2.3% to 8.7% and from 4.5% to 7.6%, respectively.
The intra- and inter-day accuracy (relative error)
ranged from 2.3% to 8.5% and from 2.4% to 6.0%,
respectively. The RSD of intra- and inter-day vari-
ability was less than 10%, which is within the limit
Table 4. Pharmacokinetic parameters of DIC and PAP in single or composed formulations administered intravenously or orally.
Intravenous Oral
Parameters    Single Composed Single Composed   
DIC PAP DIC PAP DIC PAP DIC PAP  
AUC0→∞
(h∑mg/L)
(mean n =  
83.88 ± 18.78 21.46 ± 5.71 80.34 ± 12.54 22.24 ± 4.65 24.32 ± 5.57 4.12 ± 1.02 21.52 ± 4.36 3.77 ± 0.66
6, ± SD)
MRT (h)
(mean n = 1.30 ± 0.45 0.96 ± 0.33 1.32 ± 0.30 1.56 ± 0.38 2.68 ± 0.66 1.82 ± 0.19 2.16 ± 0.71 2.14 ± 0.30
6, ± SD)   
CL (L/h)
(mean n = 0.49 ± 0.13 0.78 ± 0.23 0.49 ± 0.07 0.74 ± 0.21 0.51 ± 0.09 0.79 ± 0.18 0.49 ± 0.11 0.72 ± 0.20
6, ± SD)  
MAT (h)
(mean n = 0.72 ± 0.20 0.86 ± 0.43 1.03 ± 0.83 0.76 ± 0.27
6, ± SD)       
F
(mean n = 0.30 ± 0.07 0.21 ± 0.11 0.28 ± 0.08 0.18 ± 0.07
6, ± SD)     
Pharmacokinetic parameters of DIC and PAP, administered intravenously and orally showed no statistically significant difference between
single or composed formulations (p > 0.05).
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A1 B1
C1 D1
C2 D2
A2
B2
Figure 2. Mean plasma concentration-time profile (n = 6) for DIC and PAP in rabbit plasma after an intravenous (i.v.) or oral (p.o.)
administration of single (DIC, PAP) or composed (DIC*, PAP*) formulations
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of acceptability (± 15%) (24). These results indicate
that this method had good precision and accuracy. 
Recovery
The mean extraction recoveries of DIC were
found to be 95.78% ± 2.98 of 0.05-5 µg/mL, PAP
93.09% ± 3.29 of 0.05-6 µg/mL and IS 95.93% ±
1.38 of 5-20 µg/mL, respectively. The recoveries
were not dependent on the concentration and conse-
quently resulted in good linearity of the calibration
curves.
Evaluation of stability of samples
Stock solutions of DIC (250 µg/mL), PAP (100
µg/mL) and IS (100 µg/mL), and working solutions
of DIC, PAP and IS were observed to be over 99%
of the nominal concentrations after 5 days of storage
at 4OC, compared with freshly prepared solutions.
Similarly, working solutions of DIC, PAP and IS
were over 99 % of the nominal concentrations after
20 days of storage at -20OC. 
Short-term stability of active substances in
plasma were investigated at room temperature for 48
h. After the storage, the coefficients of variation
(CV, %) values varied from 1.21 to 2.56 for DIC
solutions and from 1.32 to 1.89 for PAP concentra-
tions.
Long-term freezer stability of plasma samples
(after 30 days of storage at -20OC) CV values for
analyzed DIC samples: 0.05, 0.25, 1.25, 5.0 µg/mL
amounted to 3.96, 2.21, 4.04 and 4.15%, respective-
ly. PAP (CV) values amounted to 4.49, 4.55, 3.89
and 4.04% for concentrations: 0.05, 0.2, 2.0, 6.0
µg/mL, respectively.
After storage in long-term freeze-thaw stability
for three cycles (-20OC, 30 days) the drugs were
regarded as stable if more than 90% was intact at the
end of the study period. The amount of the initial
concentration of DIC and PAP remaining after this
time was: 97.43 ± 2.14%, 98.32 ± 1.68%, 97.12 ±
1.89%, 98.89 ± 2.21% for DIC concentrations of
0.05, 0.25, 1.25 and 5.0 µg/mL, respectively, and
98.32 ± 2.5%, 99.03 ± 1.98%, 95.78 ± 2.08% and
98.16 ± 2.41% for PAP concentrations of 0.05, 0.2,
2.0 and 6.0 µg/mL respectively.
The results from the stability tests (Tables 3 A
and B) indicated that DIC and PAP were stable
under the conditions studied.
Pharmacokinetic study
The mean plasma concentration-time profiles
of DIC and PAP are shown in Figure 2. The phar-
macokinetic parameters of DIC and PAP were cal-
culated by non-compartmental analysis and are pre-
sented in Table 4. More than 99% of diclofenac is
bound to plasma proteins (3, 9) and papaverine is
about 90% (3), therefore, we expected changes in
the pharmacokinetic parameters of substances after
their co-administration. As compared with the phar-
macokinetic parameters, such as AUC0→∞, MRT and
CL of DIC or PAP administered intravenously and
orally, after single dose there was no statistically
significant difference between single or compound
formulations (p > 0.05). The MAT of DIC and PAP
administered as single or compound formulations
were calculated to be over 1 h and these MAT val-
ues presented no statistically significant difference
between the formulations (p > 0.05). Similarly, after
the oral administration of DIC to the rabbits, the
mean MAT was equal to 1.24 h (47). Diclofenac
penetrates to synovial fluid where concentrations
may persist even when in plasma concentrations
fall. Diclofenac is metabolized by cytochrome P450
by phase I hydroxylation and by phase II conjuga-
tion with glucuronic acid and the amino acid taurine.
Diclofenac is extensively metabolized in camels as
well as in humans, goats and cattle, and this appears
to be mediated by cytochrome P450 2C subfamily
(48, 49).
Drug-protein binding has an influence on the
distribution equilibrium of drugs. Only the free,
non-protein bound fraction of drug can leave the cir-
culatory system and diffuse into tissue. The equilib-
rium between free drug can be maintained over a
relatively long period of time because of the disso-
ciation of the drug-protein complex. The transport
function of plasma proteins is of importance for
drugs of low solubility in water. Plasma protein
binding is of significant influence on the distribution
equilibrium if the drug is polar and therefore diffus-
es slowly into tissue. If, in addition, such a substance
has a high affinity for plasma proteins, displacement
from its protein binding sites may result in a change
of distribution equilibrium and an altered pharmaco-
logic response (50).
The AUC0→∞ values of DIC or PAP after intra-
venous injection were higher than after oral admin-
istration. It was shown that bioavailability of (F)
DIC and PAP after oral administration was
decreased to over 30% for DIC and 20% for PAP,
but for some rabbits bioavailability amounted to
over 43% for both DIC and PAP. When DIC is oral-
ly administered, it is almost completely absorbed
due to the fact that it is subject to first-pass metabo-
lism. In this way about 50% of the drug reaches the
systemic circulation in the unchanged form (3).
The metabolic tracts of both of the substances
showed that it is possible that a simultaneous admin-
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istration of DIC and PAP has no influence on their
pharmacokinetics. 
In our study, oral administration of a tablet com-
prising DIC and PAP did not change the main phar-
macokinetic parameters of the active substances after
single dose. Similarly, administration of diclofenac
and misoprostol in one composed tablet did not
change the pharmacokinetics of these two drugs (4). 
CONCLUSION
Tablets comprising DIC and PAP were prepared
and all of tablets fulfilled pharmacopoeal require-
ments such as average weight, hardness and assay of
drug content. A HPLC-UV method with LLE extrac-
tion was developed and validated for the quantitative
determination of DIC and PAP in rabbit plasma. The
LLOQ of the method was 0.05 µg/mL and the sensi-
tivity was compared with previously reported HPLC-
UV methods using LLE (21) and protein precipitation
(19). The proposed method was successfully applied
to determination of DIC and PAP, after injection and
oral administration to rabbits, for use in pharmacoki-
netic study. A non-compartmental pharmacokinetic
analysis showed that oral administration of composed
tablet comprising DIC and PAP did not change the
main pharmacokinetic parameters such as MRT,
MAT, CL and bioavailability of active substances
compared with a single administration of DIC and
PAP after single dose.
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